Genelux Co. (NASDAQ:GNLX - Get Free Report) major shareholder Aladar Szalay sold 8,064 shares of Genelux stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the completion of the transaction, the insider now directly owns 1,255,730 shares in the company, valued at $4,395,055. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Aladar Szalay also recently made the following trade(s):
- On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $50,588.43.
- On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.
Genelux Stock Performance
GNLX opened at $3.45 on Thursday. Genelux Co. has a 1 year low of $3.26 and a 1 year high of $40.98. The stock's 50 day simple moving average is $5.86 and its 200-day simple moving average is $10.95.
Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.04). As a group, equities analysts expect that Genelux Co. will post -0.81 earnings per share for the current year.
Wall Street Analysts Forecast Growth
The asset beating inflation by 4x
From Colonial Metals | Ad
"Trump Loophole" Beats Inflation?
Inflation has been out of control for years.
Forcing you to work longer and harder for more money that is worth less.
By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
That's why we have released our Free Precious Metals Investment Guide that explains all the details
Several research analysts have commented on the company. HC Wainwright dropped their price target on Genelux from $35.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday, April 2nd. Benchmark reaffirmed a "speculative buy" rating and issued a $30.00 price target on shares of Genelux in a research report on Wednesday, April 3rd.
Read Our Latest Report on GNLX
Institutional Trading of Genelux
A number of institutional investors and hedge funds have recently modified their holdings of the company. Amalgamated Bank boosted its stake in Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company's stock valued at $26,000 after buying an additional 770 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Genelux by 216.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company's stock valued at $41,000 after buying an additional 2,021 shares in the last quarter. Barclays PLC boosted its stake in Genelux by 516.4% in the 3rd quarter. Barclays PLC now owns 3,384 shares of the company's stock valued at $83,000 after buying an additional 2,835 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Genelux by 89.5% in the 3rd quarter. New York State Common Retirement Fund now owns 5,495 shares of the company's stock valued at $135,000 after buying an additional 2,595 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in Genelux by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company's stock valued at $87,000 after buying an additional 1,573 shares in the last quarter. 37.33% of the stock is currently owned by institutional investors.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
